These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19095570)

  • 1. Percentage of tumor in prostatectomy specimens: a study of American Veterans.
    Vollmer RT
    Am J Clin Pathol; 2009 Jan; 131(1):86-91. PubMed ID: 19095570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percentage of tumor and tumor length in prostate biopsy specimens: a study of American veterans.
    Vollmer RT
    Am J Clin Pathol; 2008 Dec; 130(6):940-3. PubMed ID: 19019772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.
    Cheng L; Davidson DD; Lin H; Koch MO
    Cancer; 2007 Nov; 110(9):1967-72. PubMed ID: 17823907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor length in prostate cancer.
    Vollmer RT
    Am J Clin Pathol; 2008 Jul; 130(1):77-82. PubMed ID: 18550474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of radial distance of extraprostatic extension from pretherapy factors.
    Schwartz DJ; Sengupta S; Hillman DW; Sargent DJ; Cheville JC; Wilson TM; Mynderse LA; Choo R; Davis BJ
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):411-8. PubMed ID: 17869661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
    Sankin A; Tareen B; Lepor H
    Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
    Xu DD; Sun SD; Wang F; Sun L; Stackhouse D; Polascik T; Albala DM; Moul JW; Caire A; Robertson CN
    Urology; 2009 Sep; 74(3):654-8. PubMed ID: 19628263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
    Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
    BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
    J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perineural invasion is a prognostic factor for biochemical failure after radical prostatectomy.
    Jeon HG; Bae J; Yi JS; Hwang IS; Lee SE; Lee E
    Int J Urol; 2009 Aug; 16(8):682-6. PubMed ID: 19602004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.
    Erbersdobler A; Isbarn H; Steiner I; Schlomm T; Chun F; Mirlacher M; Sauter G
    Urology; 2009 Nov; 74(5):1169-73. PubMed ID: 19476978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
    Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.